Khan Muhammad Ali, Mehmood Munir, El Azzazi Hind, Shaikh Samiullah, Bhasin-Chhabra Bhavna, Gudsoorkar Prakash, Nair Sumi Sukumaran, Kodali Lavanya, Mour Girish, Swaminathan Sundararaman, Abu Jawdeh Bassam G
Division of Nephrology and Hypertension, Mayo Clinic Arizona, 5777 E. Mayo Blvd, Phoenix, AZ 85054, USA.
Medical College, The Aga Khan University, Stadium Road, Karachi 74800, Pakistan.
J Clin Med. 2025 Jul 20;14(14):5152. doi: 10.3390/jcm14145152.
The indications for immune checkpoint inhibitor (ICI) use in cancer treatment continue to expand. This is attributable to their proven anticancer activity in addition to their tolerability and favorable toxicity profile as compared to conventional chemotherapeutic agents. ICIs work by blocking the inhibitory signals between tumor cells and T-cells, thereby enhancing the T-cell cytotoxic activity to inhibit tumor growth. Because of their immune-stimulating effect, ICIs are linked to adverse renal outcomes in both native and transplanted kidneys. The risk of kidney allograft rejection in the setting of ICI use has been reported to be around 40%, leading to an increased risk of graft loss. In this report, we review the literature examining outcomes in kidney transplant recipients receiving ICIs for various oncologic indications.
免疫检查点抑制剂（ICI）在癌症治疗中的应用指征不断扩大。这归因于其已被证实的抗癌活性，以及与传统化疗药物相比的耐受性和良好的毒性特征。ICI通过阻断肿瘤细胞与T细胞之间的抑制信号发挥作用，从而增强T细胞的细胞毒性活性以抑制肿瘤生长。由于其免疫刺激作用，ICI与天然肾和移植肾的不良肾脏结局相关。据报道，在使用ICI的情况下，肾移植受者发生移植肾排斥反应的风险约为40%，导致移植肾丢失风险增加。在本报告中，我们回顾了有关接受ICI治疗各种肿瘤指征的肾移植受者结局的文献。
